RxDoctor Payments Data

Erin Omalley, MD

Cardiovascular Disease · Philadelphia, PANPI 1487628962

Payments from drug & device makers

$3,896in general payments, 2019–2025

Across 24 payments — averaging $162.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Scientific Affairs, LLC$3K
  • Abbott$135
  • Biotronik Inc.$125
  • Amgen$98
  • Heartflow, Inc.$55
  • Novartis$49
  • plus $235 from 10 others

What the payments were for

  • Consulting fees$3,20082%
  • Food & beverage$69618%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,896 in reported general payments places this provider in the 65th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$403,355
Medicare patients
730
Services billed
2,709

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban154$170,212
EliquisApixaban135$155,843
EntrestoSacubitril/Valsartan38$48,861
Repatha SureclickEvolocumab50$28,577
JardianceEmpagliflozin20$19,749
Nebivolol Hcl107$11,376
Rosuvastatin Calcium459$6,717
Valsartan166$6,640
Atorvastatin Calcium399$6,119
Metoprolol Succinate321$4,985
Ezetimibe178$4,476
Losartan Potassium180$2,556
Diltiazem 24hr Er (Cd)Diltiazem Hcl60$2,550
Amlodipine Besylate289$1,749
Carvedilol176$1,463

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$41$170,212154 claims
PfizerEliquis$14$155,843135 claims
NovartisEntresto$49$48,86138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →